HIV Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global HIV drugs market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the HIV drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The HIV Drugs market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider HIV drugs market, and compares it with other markets.
The report covers the following chapters:
Scope
Markets Covered:
1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s); Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s); Protease Inhibitors; Integrase strand transfer inhibitors (INSTIs); Others
2) By Application: Hospital Pharmacies; Retail Pharmacies; Others
3) By Administration: Oral; Parenteral
Companies Mentioned: Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Boehringer Ingelheim International GmbH
Metrics Covered: Number of Enterprises; Number of Employees
Countries: China; India; Japan; Australia; Indonesia; South Korea; USA; Brazil; UK; Germany; France; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, HIV drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the HIV drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The HIV Drugs market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider HIV drugs market, and compares it with other markets.
The report covers the following chapters:
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type, by application, by administration.
- Market Characteristics - The market characteristics section of the report defines and explains the HIV drugs market. This chapter also defines and describes goods and related services covered in the report.
- Trends and Strategies - This chapter describes the major trends shaping the global HIV drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the HIV drugs market.
- Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global HIV drugs market, estimated market shares and company profiles for the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for HIV drug companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s); Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s); Protease Inhibitors; Integrase strand transfer inhibitors (INSTIs); Others
2) By Application: Hospital Pharmacies; Retail Pharmacies; Others
3) By Administration: Oral; Parenteral
Companies Mentioned: Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Boehringer Ingelheim International GmbH
Metrics Covered: Number of Enterprises; Number of Employees
Countries: China; India; Japan; Australia; Indonesia; South Korea; USA; Brazil; UK; Germany; France; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, HIV drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Table of Contents
1. HIV Drugs Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure6. Introduction
7. Segmentation By Geography
8. HIV Drugs Market Characteristics
2. Africa HIV Drugs Market
2. Global HIV Drugs Market Competitive Landscape
2. Key Mergers and Acquisitions In The HIV Drugs Market
2. HIV Drugs Market Opportunities and Strategies
2. HIV Drugs Market Conclusions and Recommendations
2. Appendix
Executive Summary
This report describes and evaluates the global HIV drugs market. It covers three five years’ period, including, 2015 to 2020, termed the historic period, 2020 – 2025 forecast period and 2025 -2030 the forecast period.The global HIV drugs market reached a value of nearly $30,520.0 million in 2020, having increased at a compound annual growth rate (CAGR) of 8.1% since 2015. The market is expected to grow from $30,520.0 million in 2020 to $36,460.0 million in 2025 at a rate of 3.6%. The growth is mainly due to the growing prevalence of HIV and government initiatives which is expected to drive the demand for HIV drugs. The market is expected to grow from $36,460.0million in 2025 to $40,303.1 million in 2030 at a CAGR of 2.0%.
Growth in the historic period resulted from increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets. This growth was restricted by challenges due to regulatory changes, patent expiration of drugs, rise in alternative medications and low healthcare access.
Going forward, government initiatives, cheaper interest rates, development in drug discovery and cheaper interest rates will support the market growth. Side effects of HIV drugs, shortage of supply of HIV drugs, impact of COVID-19 and low rate of voluntary screening are major factors that could hinder the growth of the HIV drugs market in the future.
The HIV drugs market is segmented by type into nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and others. The non-nucleoside reverse transcriptase inhibitors were the largest segment of the HIV drugs market by type, accounting for 29.4% of the total market in 2020. Going forward, it is also is expected to be the fastest growing segment in the HIV drugs market, at a CAGR of 11.1% during 2020-2025.
The HIV drugs market is also segmented by application into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy was the largest segment of the HIV drugs market by application, accounting for 64.6% of the total market in 2020. Going forward, the others segment is expected to be the fastest growing segment in the HIV drugs market, at a CAGR of 5.4%, during 2020-2025.
The HIV drugs market is also segmented by route of admiration into oral and parenteral. The oral was the largest segment of the HIV drugs market by route of administration, accounting for 94.5% of the total market in 2020. Going forward, it is also expected to the fastest growing segment in the HIV drugs market, at a CAGR of 3.7%.
North America was the largest region in the global HIV drugs market, accounting for 51.1% of the total in 2020. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the HIV drugs market will be Africa and Asia-Pacific, where growth will be at CAGRs of 6.0% and 4.1% respectively. These will be followed by Middle East and North America, where the markets are expected to register CAGRs of 4.9% and 3.5% respectively.
The HIV drugs market is concentrated, with a small number of large players in the market. The top eight competitors in the market made up to 92.9% of the total market in 2020. Major players in the market include Gilead Sciences Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim GmbH and others.
The top opportunities in the HIV drugs market segmented by type will arise in the non-nucleoside reverse transcriptase inhibitors segment, which will gain $6,152 million of global annual sales by 2025. The top opportunities in the HIV drugs market segmented by route of administration will arise in the oral segment, which will gain $5,692.8 million of global annual sales by 2025. The top opportunities in the HIV drugs market segmented by application will arise in the hospital pharmacies segment, which will gain $3,175.7 million of global annual sales by 2025. The HIV drugs’ market size will gain the most in the USA at $2,466 million. Market-trend-based strategies for the HIV drugs market include investing in 3D bioprinting technology, new product innovations, developing multi-class combination products for HIV treatment and investing in strategic collaborations and agreements. Player-adopted strategies in the HIV drugs market include investing in expanding operations through innovative product launches, investing in collaborations and mergers and getting approvals for new drugs for HIV treatment.
The COVID-19 pandemic substantially impacted the market for HIV drugs owing to the supply chain disruptions in the production and distribution of HIV drugs caused during 2020. In addition to this, the coronavirus outbreak also impacted the HIV testing services in all the countries across the globe.
The usage of HIV and other anti-viral drugs post COVID-19 outbreak increased the demand for these drugs attributing to their usage in the treatment of COVID-19 affected patients.
To take advantage of the opportunities, the publisher recommends the HIV drug companies to focus on the use of automation, focus on combination therapy, focus on research and development of innovative products, focus on collaborations, expand in markets with high incidence of HIV, provide competitively priced offerings, premium pricing for innovative drugs, companies should focus on increasing awareness on HIV infection, companies should leverage e-commerce tools to maximize reach, focus on uneducated population and target young population.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Gilead Sciences, Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Cipla
- Aurobindo Pharma
- AbbVie
- Aspen Pharmacare Limited
- Pharmacare Ltd.
- Zion Medical
- Pfizer
- Abbott Laboratories
- Alfa Rio Química Ltda.
- Globe Quimica S/A
- Nortec Química S.A.
- Microbiológica Química e Farmacêutica
- Indústria e Comércio de Medicamentos Labogen S.A.
- AstraZeneca
- Gritstone Oncology
- Enzolytics Inc.
- BioClonetics Immunotherapeutics, Inc.
- Dewpoint Therapeutics
- ViiV Healthcare
- Lyndra Therapeutics
- Mylan N.V.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Teva Canada
- Pharmstandard
- Pharmasyntez
- R-Pharm
- Alium
- ChemRar Group
- CytoDyn Inc.
- Janssen Pharmaceutical
- Bavarian Nordic
- Emcure Pharmaceuticals
- Micro Labs Limited
- Shanghai Desano Bio Pharmaceutical
- Northeast Pharmaceutical Group Co. Ltd
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd
- Strides Arcolab Limited
- Hetero labs limited
Methodology
LOADING...
